Yazar "Caner, Burcu" için listeleme
-
Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey
Hacıoğlu, Muhammet Bekir; Köstek, Osman; Karabulut, Senem; Taştekin, Didem; Sezgin Göksu, Sema; Alandağ, Celal; Akagündüz, Baran; Bilgetekin, İrem; Caner, Burcu; Şahin, Ahmet Bilgehan; Yıldız, Birol; Köse, Fatih; Kaplan, Muhammet Ali; Gülmez, Ahmet; Doğan, Ender; Güven, Deniz Can; Gürbüz, Mustafa; Ergun, Yakup; Karaağaç, Mustafa; Demiray, Atike Gökçen; Türker, Sema; Sakalar, Teoman; Özkul, Özlem; Akın Telli, Tuğba; Şahin, Süleyman; Kılıçkap, Saadettin; Bilici, Ahmet; Erdoğan, Bülent; Çiçin, İrfan (Imprimatur Publication, 2020)Purpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of ... -
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: A Turkish Oncology Group Study
Hızal, Mutlu; Bilgin, Burak; Paksoy, Nail; Açıkgöz, Özgür; Sezer, Ahmet; Gürbüz, Mustafa; Ak, Naziye; Yücel, Şebnem; Ayhan, Murat; Erol, Cihan; Demirkıran, Aykut; Mandel, Nil Molinas; Shbair, Abdallah; Gökmen, İvo; Başoğlu, Tuğba; Paydaş, Semra; Demiray, Atike Gökçen; İriağaç, Yakup; Şakalar, Teoman; Zeynelgil, Esra; Tatlı, Ali Murat; Bahçeci, Aykut; Güven, Deniz Can; Caner, Burcu; Can, Alper; Gülmez, Ahmet; Karakaş, Yusuf; Yalçın, Bülent; Demirkazık, Ahmet; Bilici, Ahmet; Aydıner, Adnan; Yumuk, Perran Fulden; Şendur, Mehmet Ali Nahit (Springer, 2022)Introduction Osimertinib, an irreversible third-generation EGFR-TKI, is the standard of care for second-line treatment of T790M-mutant advanced NSCLC patients whose disease progressed after first-line EGFR-TKI therapy. In ...